(PFE) Pfizer - Overview
Stock: Medicines, Vaccines, Biosimilars, Injectables, Oncology
| Risk 5d forecast | |
|---|---|
| Volatility | 24.1% |
| Relative Tail Risk | -4.65% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.37 |
| Alpha | -4.09 |
| Character TTM | |
|---|---|
| Beta | 0.615 |
| Beta Downside | 0.521 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.27% |
| CAGR/Max DD | -0.19 |
EPS (Earnings per Share)
Revenue
Description: PFE Pfizer February 28, 2026
Pfizer (NYSE:PFE) is a global biopharmaceutical leader that discovers, develops, manufactures, markets and distributes a broad portfolio of medicines and vaccines across therapeutic areas such as cardiovascular disease, infectious disease, oncology, immunology and rare diseases. Its flagship brands include Eliquis, Prevnar, Comirnaty, Paxlovid and a growing line-up of biosimilars and mRNA-based candidates, while the firm also offers contract-manufacturing services to a diverse customer base that spans hospitals, pharmacies and government agencies.
In its most recent fiscal year (2025), Pfizer reported revenue of $100.3 billion, a 4.2 % increase YoY, driven largely by strong oncology sales (e.g., Ibrance and Tivdak) and the resurgence of its biosimilar pipeline. Adjusted earnings per share rose to $4.15, and the company reinvested $12.5 billion into R&D, reflecting a continued focus on next-generation mRNA therapeutics and antibody-drug conjugates. COVID-19 product sales continued to decline, falling 78 % from their 2022 peak, underscoring the need for diversification beyond pandemic-related revenue.
Key sector drivers for Pfizer include the aging global population, which fuels demand for chronic-disease treatments, and the accelerating adoption of biologics and mRNA platforms that are reshaping drug development economics. Pricing pressure from payers and heightened regulatory scrutiny remain headwinds, while strategic collaborations-such as the AI-focused partnership with Boltz, PBC and ongoing alliances with BioNTech, Bristol-Myers Squibb and Merck KGaA-provide pathways to accelerate innovation and improve cost efficiency.
For a deeper quantitative dive, you may want to explore additional analytics on ValueRay.
Headlines to watch out for
- Paxlovid sales decline impacts overall revenue
- New drug approvals drive future growth
- Biosimilar competition erodes established product sales
- Research and development costs pressure margins
- Regulatory hurdles delay market entry for new therapies
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 7.77b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.25 > 1.0 |
| NWC/Revenue: 9.45% < 20% (prev 11.57%; Δ -2.12% < -1%) |
| CFO/TA 0.06 > 3% & CFO 11.71b > Net Income 7.77b |
| Net Debt (66.27b) to EBITDA (16.78b): 3.95 < 3 |
| Current Ratio: 1.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (5.69b) vs 12m ago -0.30% < -2% |
| Gross Margin: 70.33% > 18% (prev 0.67%; Δ 6.97k% > 0.5%) |
| Asset Turnover: 29.69% > 50% (prev 29.82%; Δ -0.13% > 0%) |
| Interest Coverage Ratio: 3.82 > 6 (EBITDA TTM 16.78b / Interest Expense TTM 2.67b) |
Altman Z'' 3.23
| A: 0.03 (Total Current Assets 42.90b - Total Current Liabilities 36.98b) / Total Assets 208.16b |
| B: 0.55 (Retained Earnings 114.61b / Total Assets 208.16b) |
| C: 0.05 (EBIT TTM 10.19b / Avg Total Assets 210.78b) |
| D: 0.88 (Book Value of Equity 107.02b / Total Liabilities 121.39b) |
| Altman-Z'' Score: 3.23 = A |
Beneish M -3.24
| DSRI: 0.82 (Receivables 11.87b/14.78b, Revenue 62.58b/63.63b) |
| GMI: 0.95 (GM 70.33% / 66.76%) |
| AQI: 1.02 (AQ_t 0.69 / AQ_t-1 0.68) |
| SGI: 0.98 (Revenue 62.58b / 63.63b) |
| TATA: -0.02 (NI 7.77b - CFO 11.71b) / TA 208.16b) |
| Beneish M-Score: -3.24 (Cap -4..+1) = AA |
What is the price of PFE shares?
Over the past week, the price has changed by -0.75%, over one month by -2.78%, over three months by +5.98% and over the past year by +9.56%.
Is PFE a buy, sell or hold?
- StrongBuy: 7
- Buy: 2
- Hold: 15
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the PFE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.4 | 6.8% |
| Analysts Target Price | 28.4 | 6.8% |
PFE Fundamental Data Overview March 14, 2026
P/E Forward = 9.1743
P/S = 2.4406
P/B = 1.7859
P/EG = 13.7734
Revenue TTM = 62.58b USD
EBIT TTM = 10.19b USD
EBITDA TTM = 16.78b USD
Long Term Debt = 60.81b USD (from longTermDebt, last quarter)
Short Term Debt = 3.48b USD (from shortTermDebt, last quarter)
Debt = 67.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 66.27b USD (from netDebt column, last quarter)
Enterprise Value = 206.55b USD (152.73b + Debt 67.42b - CCE 13.60b)
Interest Coverage Ratio = 3.82 (Ebit TTM 10.19b / Interest Expense TTM 2.67b)
EV/FCF = 22.76x (Enterprise Value 206.55b / FCF TTM 9.08b)
FCF Yield = 4.39% (FCF TTM 9.08b / Enterprise Value 206.55b)
FCF Margin = 14.50% (FCF TTM 9.08b / Revenue TTM 62.58b)
Net Margin = 12.42% (Net Income TTM 7.77b / Revenue TTM 62.58b)
Gross Margin = 70.33% ((Revenue TTM 62.58b - Cost of Revenue TTM 18.57b) / Revenue TTM)
Gross Margin QoQ = 69.97% (prev 74.95%)
Tobins Q-Ratio = 0.99 (Enterprise Value 206.55b / Total Assets 208.16b)
Interest Expense / Debt = 1.05% (Interest Expense 711.0m / Debt 67.42b)
Taxrate = 21.0% (US default 21%)
NOPAT = 8.05b (EBIT 10.19b * (1 - 21.00%))
Current Ratio = 1.16 (Total Current Assets 42.90b / Total Current Liabilities 36.98b)
Debt / Equity = 0.78 (Debt 67.42b / totalStockholderEquity, last quarter 86.48b)
Debt / EBITDA = 3.95 (Net Debt 66.27b / EBITDA 16.78b)
Debt / FCF = 7.30 (Net Debt 66.27b / FCF TTM 9.08b)
Total Stockholder Equity = 89.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.69% (Net Income 7.77b / Total Assets 208.16b)
RoE = 8.67% (Net Income TTM 7.77b / Total Stockholder Equity 89.58b)
RoCE = 6.78% (EBIT 10.19b / Capital Employed (Equity 89.58b + L.T.Debt 60.81b))
RoIC = 5.32% (NOPAT 8.05b / Invested Capital 151.33b)
WACC = 5.93% (E(152.73b)/V(220.15b) * Re(8.18%) + D(67.42b)/V(220.15b) * Rd(1.05%) * (1-Tc(0.21)))
Discount Rate = 8.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.34%
[DCF] Terminal Value 83.89% ; FCFF base≈9.38b ; Y1≈7.66b ; Y5≈5.40b
[DCF] Fair Price = 17.17 (EV 163.90b - Net Debt 66.27b = Equity 97.63b / Shares 5.69b; r=5.93% [WACC]; 5y FCF grow -22.07% → 2.90% )
EPS Correlation: -45.84 | EPS CAGR: -21.29% | SUE: 0.90 | # QB: 10
Revenue Correlation: -58.19 | Revenue CAGR: -9.63% | SUE: 0.37 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.70 | Chg7d=-0.000 | Chg30d=-0.016 | Revisions Net=-2 | Analysts=18
EPS current Year (2026-12-31): EPS=2.96 | Chg7d=+0.000 | Chg30d=+0.001 | Revisions Net=-2 | Growth EPS=-8.0% | Growth Revenue=-2.2%
EPS next Year (2027-12-31): EPS=2.83 | Chg7d=+0.000 | Chg30d=+0.013 | Revisions Net=-1 | Growth EPS=-4.4% | Growth Revenue=-3.7%
[Analyst] Revisions Ratio: -0.25 (3 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.1% (Discount Rate 8.2% - Earnings Yield 5.1%)
[Growth] Growth Spread = -4.2% (Analyst -1.1% - Implied 3.1%)